Showing 1521-1530 of 1717 results for "".
- Meta-Analysis Shows Aerobic Exercise After Stroke Correlates With Improved Endurance and Walking Speedhttps://practicalneurology.com/news/meta-analysis-shows-aerobic-exercise-after-stroke-correlates-with-improved-endurance-and-walking-speed/2468993/A meta-analysis published in the Journal of the American Heart Association found that survivors of stroke who completed aerobic exercise programs achieved improvements in endurance and walking ability. Overall, participant
- Studies Aim to Address Differences in Health Care for Dementia for LGBT Communityhttps://practicalneurology.com/news/studies-aim-to-address-differences-in-health-care-for-dementia-for-lgbt-community/2468961/Finding from the Aging With Pride: IDEA study (NCT03550131), presented at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 show that a strong research-community partnership is necessary for th
- Phase 2 Trial of Niflamapimod for Dementia With Lewy Bodies Beginshttps://practicalneurology.com/news/phase-2-trial-of-niflamapimod-for-dementia-with-lewy-bodies-begins-1/2468960/A phase 2 proof-of-concept clinical study, AscenD-LB (NCT04001517) has begun for neflamapimod (EIP Pharma,Cambridge, MA) as a treatment for the cognitive dysfunction associated with dementia with Lewy bodies (DLB). Accounting for appro
- Paramagnetic Rim Lesions Predict Conversion to Clinical MS in Radiologically Isolated Syndromehttps://practicalneurology.com/news/paramagnetic-rim-lesions-predict-conversion-to-clinical-ms-in-radiologically-isolated-syndrome/2485881/In a prospective multicenter cohort study published in JAMA Neurology, paramagnetic rim lesions (PRLs) detected on susceptibility-sensitive MRI in individuals with radiologically isolated syndrome (RIS) were associated with increased risk of developing clinical multiple sclerosis (MS). A
- Satralizumab Treatment for MOGAD—Positive Results Announced from Phase 3 Trialhttps://practicalneurology.com/news/satralizumab-treatment-for-mogadpositive-results-announced-from-phase-3-trial/2485804/Results of the phase 3 METEOROID clinical trial (NCT05271409) showed that satralizumab (Roche, Basel, Switzerland; Genentech, South San Francisco, CA) treatment prevented and/or delayed time to myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) relapses, representing the firs
- Real-World Data Support Kesimpta as First-Line Therapy in Early Relapsing Multiple Sclerosishttps://practicalneurology.com/news/real-world-data-support-kesimpta-as-first-line-therapy-in-early-relapsing-multiple-sclerosis/2485638/Real-world data from a prospective, noninterventional study suggest that Kesimpta (ofatumumab; Novartis, East Hanover, NJ) is associated with higher treatment retention, lower relapse activity, and favorable safety outcomes compared with interferon ß-1 or glatiramer acetate when used as first-lin
- Maternal COVID-19 Exposure Linked to Neurodevelopmental Risk in Childrenhttps://practicalneurology.com/news/maternal-covid-19-exposure-linked-to-neurodevelopmental-risk-in-children/2485480/Children exposed to maternal COVID-19 (SARS-CoV-2 infection) in utero had a higher likelihood of receiving a neurodevelopmental diagnosis by age 3 years, with the strongest associations observed following third-trimester exposure and among male offspring, according to a large retrospective cohort
- Blood-Based Biomarkers Track Progression Risk in Subjective Cognitive Declinehttps://practicalneurology.com/news/blood-based-biomarkers-track-progression-risk-in-subjective-cognitive-decline/2485479/Longitudinal changes in blood-based biomarkers of Alzheimer disease (AD) were associated with cognitive decline and progression to mild cognitive impairment (MCI) or dementia among individuals with subjective cognitive decline (SCD), according to results of a prospective cohort study published in
- Study Investigates Semaglutide Treatment for Large Vessel Occlusion Stroke With and Without IV Thrombolysishttps://practicalneurology.com/news/study-investigates-semaglutide-treatment-for-large-vessel-occlusion-stroke-with-and-without-iv-thrombolysis/2485296/Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide did not significantly improve functional recovery overall in people with acute large vessel occlusion (LVO) stroke undergoing reperfusion therapy but was associated with reduced intracranial hemorrhage (ICH) risk an
- Promising Data Presented for Investigational Oral Treatment for People with Alzheimer’shttps://practicalneurology.com/news/promising-data-presented-for-investigational-oral-treatment-for-people-with-alzheimers/2484840/Once-daily treatment with tazbentetol (SPG302; Spinogenix, Los Angeles, CA) was associated with rapid and sustained improvements in cognitive and functional measures in a study of adults with mild-to-moderate Alzheimer disease (AD), according to topline results presented at the 18th annual Clinic